News Column

Thomas Dubinski joins Dyadic as Chief Financial Officer

August 13, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), is a global biotechnology company whose patented and proprietary technologies are used to discover, develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced the appointment of Thomas "Tom" Dubinski as Vice President and Chief Financial Officer. Tom will be responsible for leading the financial and information technology operations for Dyadic and will succeed Michael Faby effective August 4, 2014 (see also Dyadic International, Inc.).

Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO

Prior to joining Dyadic, Tom held senior management positions at Fortune 500 businesses with global operations. From 2012 to 2014, Tom served as a management consultant at CFO Solutions. Tom previously served as Finance Officer for Walgreens Infusion Services where he was responsible for the finance function of a division with approximately $1 billion in revenue, and he has also held other senior positions within Walgreens corporate finance from 2007 to 2011. Prior to Walgreens, Tom was Director of Finance for Novartis Medical Nutrition from 2005 to 2006 and Chief Financial Officer of Metal Technology Solutions, a private manufacturer of precision metal components, from 2002 to 2004. Tom is also an 18 year veteran of Abbott Laboratories, where he had senior finance leadership roles in the areas of commercial operations, product development and manufacturing from 1984 to 2002.

Mark Emalfarb, Chief Executive Officer said, "I strongly believe Tom possesses the skills to help us build upon our existing infrastructure to ensure financial accuracy as we embark upon becoming an SEC reporting company. He also has significant international experience and has a proven track record of success in acquisitions and expansions into new markets in the U.S., Europe and Asia. After a thorough search, with many qualified and experienced candidates, we believe Tom to be the right person to help us with our commitment to further refine and implement our growth strategies."

Tom added, "What excited me most about the opportunity with Dyadic was the passion and vision of its founder and other members of the management team, who shared their belief for the unlimited and untapped potential for the development and manufacturing of enzymes and other proteins into several diverse applications. I look forward to working with my new team, corporate partners and highly regarded licensees in finding the best ways to monetize the C1 technology platform and to create value for shareholders."

Tom is a CPA and received his Bachelor of Science in Accounting from the University of Illinois, Champaign-Urbana. Tom's business address will be: 140 Intracoastal Pointe Drive, Suite 404, Jupiter, Florida 33477. Tom will receive an annual salary of $200,000 and has been granted 200,000 options to purchase Dyadic's common stock at an exercise price per share equal to the fair market value of the shares on the date of the option grant.

Keywords for this news article include: Technology, Investment and Finance, Dyadic International Inc..

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters